Trials in progress
Expert-Guided Poster Tour 05

Saturday 16 March
13:30 - 15:30

Location: Green Area, Room B
Chairs: A.S. Bjartell, Malmö (SE)
    M. De Santis, Berlin (DE)

The Expert-Guided Poster Tour is an innovative session type. The Tour aims to provide an interactive platform informing delegates on the real essentials and providing in-depth information on the different research projects. Poster viewing of 30 minutes after which two experts, will ask questions to individuals and groups of poster presenters.

13:30 - 13:33
Introduction
A.S. Bjartell, Malmö (SE)
M. De Santis, Berlin (DE)

PT116
Baseline features and treatment-decision making in patients with prostate cancer enrolled in the United in Fight against prOstate (UFO) cancer registry


¹Fudan University Shanghai Cancer Center, Dept. of Urology, Shanghai, China, ²Kindai University Faculty of Medicine, Dept. of Urology, Osaka, Japan, ³West China Hospital, Sichuan University, Dept. of Urology, Chengdu, China, ⁴National University Hospital, National University Health System, Dept. of Urology, Singapore, Singapore, ⁵Hirosaki University Graduate School of Medicine, Dept. of Urology, Hirosaki Aomori, Japan, ⁶Chulalongkorn University, Dept. of Surgery, Bangkok, Thailand, ⁷Institute Urology and Nephrology, Hospital Kuala Lumpur, Dept. of Urology, Kuala Lumpur, Malaysia, ⁸Gangnam Severance Hospital, Yonsei University College of Medicine, Dept. of Urology and Urological Science Institute, Seoul, South Korea, ⁹Rajeev Gandhi Cancer Institutes & Research Centre, Uro Oncology Services, New Delhi, India, ¹⁰National Taiwan University Hospital, Dept. of Urology, Taipei, Taiwan, ¹¹National Cancer Centre, Division of Medical Oncology, Singapore, Singapore, ¹²Faculty of Medicine, University of Malaya, Dept. of Surgery, Kuala Lumpur, Malaysia, ¹³Faculty of Medicine, Prince of Songkla University, Dept. of Surgery, Songkhla, Thailand, ¹⁴Asan Medical Center, University of Ulsan College of Medicine, Dept. of Urology, Seoul, South Korea, ¹⁵Taipei Veterans General Hospital, Dept. of Urology, Taipei, Taiwan, ¹⁶Janssen Research & Development, LLC, Epidemiology, Raritan, United States of America, ¹⁷Janssen (China) Research & Development Center, SDS China Dept, Shanghai, China, ¹⁸Janssen, GCDO-MAO, Selangor, Malaysia, ¹⁹Janssen Asia-Pacific, Medical Affairs, Sydney, Australia, ²⁰Janssen Research & Development, Epidemiology, Singapore, Singapore
Aims and objectives of this presentation
PT116

PT117

PROPEL: A randomized phase III trial evaluating the efficacy and safety of olaparib combined with abiraterone as first-line therapy in patients with metastatic castration-resistant prostate cancer (mCRPC)

By: Clarke N.W. ¹, Armstrong A.J. ², Thiery-Vuillemin A. ³, Oya M. ⁴, Ye D. ⁵, Mateo J. ⁶, Goessl C. ⁷, Kang J. ⁷, Liu S. ⁷, Saad F. ⁸
¹The Christie and Salford Royal Hospitals, Dept. of Surgery, Salford, United Kingdom, ²Duke Cancer Institute, Duke Prostate and Urologic Cancer Center, Durham, United States of America, ³CHU Besançon, CU-PH Medical Oncology, Besançon, France, ⁴Keio University, Dept. of Urology, Tokyo, Japan, ⁵Fudan University Shanghai Cancer Center, Dept. of Urology, Shanghai, China, ⁶Vall d’Hebron Institute of Oncology, Prostate Cancer Translational Research Group, Barcelona, Spain, ⁷AstraZeneca, Global Medicines Development, Gaithersburg, United States of America, ⁸Centre Hospitalier de l’Université de Montréal, Dept. of Surgery, Montréal, Canada

Aims and objectives of this presentation
PT117

PT118

Design of phase 1b/2 study of oral VERU-111, an α and β-tubulin inhibitor, for the treatment of metastatic castration and androgen blocking agent resistant prostate cancer

By: Getzenberg R. ¹, Markowski M.C. ², Eisenberger M.A. ², Antonarakis E.S. ², Yu E.Y. ³, Barnette G. ⁴, Rodriguez D. ⁴, Steiner M.S. ⁴
¹Nova Southeastern University, Dr. Kiran C. Patel College of Allopathic Medicine, Fort Lauderdale, FL, United States of America, ²Johns Hopkins University, Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, United States of America, ³University of Washington, Dept. of Oncology, Seattle, WA, United States of America, ⁴Veru Inc, Veru, Miami, FL, United States of America

Aims and objectives of this presentation
PT118

PT119

A phase 2, dose finding, placebo-controlled, study of zuclomiphene citrate to alleviate the frequency and severity of hot flashes caused by androgen deprivation in men with advanced prostate cancer

By: Getzenberg R. ¹, Rodriguez D. ², Hancock M. ³, Fisch H. ², Steiner M. ²
¹Nova Southeastern University, Dr. Kiran C. Patel College of Allopathic Medicine, Fort Lauderdale, FL, United States of America, ²Veru Inc, Clinical Operations, Miami, FL, United States of America, ³Hancock Consulting, Biostatistics, Memphis, TN, United States of America

Aims and objectives of this presentation
PT119
Comparing HIFU versus radical prostatectomy in low and intermediate risks prostate cancer: The early data of the HiFi study

By: Rischmann P. 1, Gelet A. 2, Villers A. 3, Coloby P. 4, Crouzet S. 2
1Hôpital Rangueil CHU, Dept. of Urology, Andrology and Renal Transplant, Toulouse, France, 2Hôpital Edouard Herriot, Dept. of Urology and Transplantation Surgery, Lyon, France, 3Hôpital Huriez, Dept. of Urology, Lille, France, 4Hôpital Pontoise, Dept. of Urology, Pontoise, France

Aims and objectives of this presentation
PT120

Novel and feasible methodology to obtain LE1 evidence for BPS treatment. Implementing the combined N-of-1 trial design

By: Janssen D.A.W. 1, Hoogenboom T. 2, Heesakkers J.P.F.A. 1
1Radboudumc, Dept. of Urology, Nijmegen, The Netherlands, 2Radboudumc, IQhealthcare, Nijmegen, The Netherlands

Aims and objectives of this presentation
PT121

Stopping or maintaining oral anticoagulation in patients undergoing photoselective vaporization of the prostate (SOAP) surgery for benign prostate obstruction: A multicentre randomized controlled trial

1Clinique Pasteur, Dept. of Urology, Toulouse, France, 2University Hospital Tours, Dept. of Urology, Tours, France, 3University Hospital Rennes, Dept. of Urology, Rennes, France, 4University Hospital Grenoble, Dept. of Urology, Grenoble, France, 5University Hospital Limoges, Dept. of Urology, Limoges, France, 6Cochin Hospital, Dept. of Urology, Paris, France, 7Private Hospital of Cotes d’Armor, Dept. of Urology, Plerin, France, 8Conception Hospital, Dept. of Urology, Marseille, France, 9Private Hospital of Louviere, Dept. of Urology, Lille, France, 10University Hospital Angers, Dept. of Urology, Angers, France, 11University Hospital Brest, Dept. of Urology, Brest, France, 12Clinique Pasteur, Dept. of Cardiovascular Medicine, Toulouse, France, 13University Grenoble-Alpes, University Hospital, Dept. of Anaesthesiology and Intensive Care Medicine, Grenoble, France, 14Assistance Publique-Hôpitaux de Paris, Cochin University Hospital, Dept. of Anaesthesiology and Intensive Care., Paris, France, 15University Hospital of Toulouse Rangueil, Dept. of Haematology, Toulouse, France, 16Clinique Pasteur, Dept. of Anaesthesiology and Intensive Care, Toulouse, France

Aims and objectives of this presentation
PT122
The effects of sequential mitomycin and bacillus Calmette-Guérin treatment versus bacillus Calmette-Guérin monotherapy in patients with high risk non-muscle invasive bladder cancer: Mito-bcg (EudraCT-2017-004540-37)

By: De Nunzio C. 1, Nacchia A. 1, Simone G. 2, Leonardo C. 3, Gallucci M. 2, Tubaro A. 1

1 Sapienza University of Rome, Sant’Andrea Hospital, Dept. of Urology, Rome, Italy, 2 IFO, Istituto Nazionale Tumori Regina Elena Hospital, Dept. of Urology, Rome, Italy, 3 Sapienza University of Rome, Umberto I Hospital, Dept. of Urology, Rome, Italy

Aims and objectives of this presentation

A phase 2, randomized study of nivolumab or nivolumab plus BMS-986205 with or without intravesical bacillus Calmette-Guerin in patients with bacillus Calmette-Guerin–unresponsive, high-risk, non-muscle invasive bladder cancer: CheckMate 9UT


1 Radboud University Medical Centre, Dept. of Urology, Nijmegen, The Netherlands, 2 Technical University of Munich, Dept. of Urology, Munich, Germany, 3 Fundació Puigvert, Autonomous University of Barcelona, Dept. of Urology, Barcelona, Spain, 4 University of California, San Francisco, Dept. of Urology, San Francisco, United States of America, 5 Vanderbilt University School of Medicine, Dept. of Urologic Surgery, Nashville, United States of America, 6 Carolina Urologic Research Center, Dept. of Urology, Myrtle Beach, United States of America, 7 University of Minnesota, Dept. of Urology, Minneapolis, United States of America, 8 The University of Chicago Medicine, Dept. of Surgery, Chicago, United States of America, 9 University of Tsukuba, Dept. of Urology, Tsukuba, Japan, 10 University of Kansas Medical Center, Dept. of Urology, Kansas City, United States of America, 11 Bristol-Myers Squibb, Princeton, United States of America, 12 Bristol-Myers Squibb, Dept. of Clinical Biostatistics, Princeton, United States of America, 13 Bristol-Myers Squibb, Dept. of Clinical Pharmacology and Pharmcometrics, Princeton, United States of America, 14 Bristol-Myers Squibb, Dept. of Translational Medicine, Princeton, United States of America, 15 Bristol-Myers Squibb, Dept. of Clinical Protocol, Princeton, United States of America, 16 Bristol-Myers Squibb, Dept. of Clinical Operations, Princeton, United States of America, 17 Bristol-Myers Squibb, Dept. of Clinical Trials, Bladder Cancer Program, Princeton, United States of America, 18 Bristol-Myers Squibb, Dept. of Clinical Trials, Princeton, United States of America, 19 Bristol-Myers Squibb, Dept. of Development, Princeton, United States of America, 20 Johns Hopkins University School of Medicine, Departments of Oncology and Urology, Baltimore, United States of America

Aims and objectives of this presentation

PURE-02: An open label, multicenter, single-arm, phase 2 study of neoadjuvant pembrolizumab (Pembro), preceding radical nephroureterectomy (RNU), for
patients with localized high-risk urothelial carcinoma of the upper urinary tract (UTUC)

By: Necchi A. 1, Raggi D. 1, Gust K. 2, D'Andrea D. 2, Briganti A. 3, Capitanio U. 3, Colecchia M. 1, Chung J. 4, Ali S. 4, Ross J. 4, Montorsi F. 3, Shariat S. 2

1 Fondazione IRCCS Istituto Nazionale dei Tumori, Dept. of Medical Oncology, Milan, Italy, 2 Medical University of Vienna, Dept. of Urology, Vienna, Austria, 3 Vita Salute San Raffaele University, Urological Research Institute (URI), Milan, Italy, 4 Foundation Medicine, Foundation Medicine, Cambridge, United States of America

Aims and objectives of this presentation

PT125

PT126

A phase 3 study to evaluate enfortumab vedotin (EV) versus chemotherapy in patients with previously treated locally advanced or metastatic urothelial cancer (la/mUC): EV-301, a trial-in-progress

By: Petrylak D. 1, Rosenberg J. 2, Duran I. 3, Loriot Y. 4, Sonpavde G. 5, Wu C. 6, Gartner E. 7, Melhem-Bertrand A. 8, Powles T. 9

1 Yale University School of Medicine, Dept. of Medical Oncology and Urology, New Haven, United States of America, 2 Memorial Sloan Kettering Cancer Center, Dept. of Genitourinary Oncology Service, New York City, United States of America, 3 Hospital Universitario Marqués de Valdecilla, Dept. of Medical Oncology, Santander, Spain, 4 Institut Gustave Roussy, Dept. of Medical Oncology, Paris, France, 5 Dana Farber Cancer Institute, Dept. of Medical Oncology, Boston, United States of America, 6 Astellas Pharma US, Inc., Dept. of Biostatistics, Northbrook, United States of America, 7 Seattle Genetics, Inc., Dept. of Clinical Research, Bothell, United States of America, 8 Astellas Pharma US, Inc., Development Medical Sciences, Oncology, Northbrook, United States of America, 9 Queen Mary University of London, Barts Cancer Institute, London, United Kingdom

Aims and objectives of this presentation

PT126

PT127

ATLAS: A phase 2, open-label study of rucaparib in patients with locally advanced or metastatic urothelial carcinoma


1 Hospital Del Mar, Dept. of Genitourinary Cancer Unit, Barcelona, Spain, 2 Studienpraxis Urologie, Dept. of Urologic Oncology, Nurtingen, Germany, 3 Gustave Roussy Cancer Campus, Dept. of Cancer Medicine, Villejuif, France, 4 Fondazione IRCCS Istituto Nazionale dei Tumori, Dept. of Medical Oncology, Milan, Italy, 5 Huntsman Cancer Institute, University of Utah, Dept. of Genitourinary Oncology Program, Salt Lake City, United States of America, 6 Guy’s and St. Thomas’ NHS Foundation Trust, Dept. of Medical Oncology, London, United Kingdom, 7 Stanford University School of Medicine, Dept. of Urologic Oncology Clinic, Stanford, United States of America, 8 University of Iowa and Holden Comprehensive Cancer Center, Dept. of Division of Hematology, Iowa City, United States of America, 9 Clovis Oncology, Inc., Dept. of Clinical Science, Boulder,
Scientific Programme - EAU19 Barcelona

Aims and objectives of this presentation
PT127

**PT128**

Post-nephrectomy adjuvant therapy for localized renal cell carcinoma (RCC): The phase III randomized, placebo-controlled CheckMate 914 study of nivolumab plus ipilimumab in patients at high risk of relapse

By: Bex A. 1, Russo P. 2, Tomita Y. 3, Grunwald V. 4, Ramirez L.M. 5, McHenry M.B. 6, Motzer R.J. 7

1 Netherlands Cancer Institute, Dept. of Urology, Amsterdam, The Netherlands, 2 Memorial Sloan Kettering Cancer Center, Dept. of Surgery, New York, United States of America, 3 Niigata University Graduate School of Medical and Dental Sciences, Dept. of Molecular Oncology, Niigata, Japan, 4 Hannover Medical School, Dept. of Hematology, Hemostasis, Oncology, and Stem Cell Transplantation, Hannover, Germany, 5 Bristol-Myers Squibb, Dept. of Research & Development Oncology, Princeton, United States of America, 6 Bristol-Myers Squibb, Dept. of Global Biometric Sciences, Princeton, United States of America, 7 Memorial Sloan Kettering Cancer Center, Dept. of Medicine, New York, United States of America

Aims and objectives of this presentation
PT128

**PT129**

Real world evidence in renal cell carcinoma: A national, prospective, non-interventional study of nivolumab in patients with advanced renal cell carcinoma after prior therapy (NORA)

By: Grimm M-O. 1, Grünwald V. 2, Müller-Huesmann H. 3, Schostak M. 4, Schultze-Seemann W. 5, Bedke J. 6

1 Jena University Hospital, Dept. of Urology, Jena, Germany, 2 University Hospital Essen, Clinic for Internal Medicine (Tumor Research) and Clinic for Urology, Essen, Germany, 3 Brüderkrankenhaus St. Josef, Dept. of Internal Medicine, Hematology and Oncology, Paderborn, Germany, 4 University Hospital Magdeburg, Dept. of Urology and Pediatric Urology, Magdeburg, Germany, 5 University of Freiburg, Faculty of Medicine, Dept. of Urology, Freiburg, Germany, 6 Eberhard Karls University, Dept. of Urology, Tübingen, Germany

Aims and objectives of this presentation
PT129

**PT130**

Pilot results from the laparoscopic entry technique in renal surgery: A randomised controlled trial comparing open (Hasson) versus closed (Veress) techniques
Aims and objectives of this presentation

PT130

The iROC trial: An RCT comparing intracorporeal robot-assisted vs open radical cystectomy for bladder cancer


1University College London, Dept. of Urology, London, United Kingdom, 2University College London, Surgical and Interventional Trials Unit, London, United Kingdom, 3University College London, Dept. of Statistical Science, London, United Kingdom, 4Guy's Hospital, Dept. of Urology, London, United Kingdom, 5University College London Hospital, Dept. of Anaesthetics, London, United Kingdom, 6University College London, Division of Surgical & Interventional Sciences, London, United Kingdom, 7University of Sheffield, Dept. of Health Economics and Decision Science, Sheffield, United Kingdom, 8Lister Hospital, Stevenage, Dept. of Urology, Stevenage, United Kingdom, 9University of Sheffield, Dept. of Urology, Sheffield, United Kingdom, 10Royal Devonshire and Exeter NHS Trust, Dept. of Urology, Exeter, United Kingdom, 11Royal Berkshire Hospital, Dept. of Urology, Reading, United Kingdom, 12North Bristol NHS Trust, Dept. of Urology, Bristol, United Kingdom, 13University College London Hospital, Dept. of Urology, London, United Kingdom

Aims and objectives of this presentation

PT131

Solutions towards implementing a multisystem cell therapy for improvement of urinary continence

By: Mohr-Haralampieva D., Prange J., Sousa R., Schmid F., Eberli D.
University of Zurich, Dept. of Urology, Zurich, Switzerland

Aims and objectives of this presentation

PT132

NeuroSAFE PROOF: A multi-centre feasibility study to evaluate the ability to randomize men with prostate cancer into an RCT comparing NeuroSAFE robotic-assisted radical prostatectomy (RARP) to standard RARP

By: Dinneen E. 1, Haider A. 2, Allen C. 3, Briggs T. 4, Nathan S. 4, Brew-Graves C. 1, Freeman A. 2, Oakley N. 5, Rowe E. 6, Persad R. 6, Shaw G. 1

Aims and objectives of this presentation

PT133
Aims and objectives of this presentation

PT134

Neo-adjUvant veRsus AdjuvaNt chemotherapy in upper tract Urothelial carcinoma: A feaSibility phase II randomized clinical trial (“URANUS”)

By: Palou J. 1, Maroto P. 2, Osanto S. 3, Bellmunt J. 4, Beisland C. 5, Roupret M. 6, European Uro-Oncology Group (EUOG)

1Fundació Puigvert, Dept. of Urology, Barcelona, Spain, 2Hospital de Sant Pau, Dept. of Urology, Barcelona, Spain, 3Leiden University Medical Center, Dept. of Urology, Leiden, The Netherlands, 4Hospital del Mar, Dept. of Urology, Barcelona, Spain, 5Haukeland University Hospital, Dept. of Urology, Bergen, Norway, 6CHU la Pitié-Salpetriere, Dept. of Urology, Paris, France

Aims and objectives of this presentation

PT134